Document is current
Any future updates will be listed below
-
Authors
Yashar, William M.
Kong, Garth
VanCampen, Jake
Curtiss, Brittany M.
Coleman, Daniel J.
Carbone, Lucia
Yardimci, Galip Gürkan
Maxson, Julia E.
Braun, Theodore P. https://orcid.org/0000-0002-6248-2143
-
Funding
Funding for this research was provided by:
National Institutes of Health (T32 GM109835: Medical Scientist Training Program of Oregon Health and Science University)
American Society of Hematology (Research Restart Award, Scholar Award)
- License Information
-
More Information
Article History
Received: 15 January 2022
Accepted: 15 June 2022
First Online: 4 July 2022
Declarations
:
: Not applicable.
: Not applicable.
: WMY potential competing interests – WMY is a former employee of Abreos Biosciences, Inc. and was compensated in part with common stock options. Pursuant to the merger and reorganization agreement between Abreos Biosciences, Inc. and Fimafeng, Inc., WMY surrendered all of his common stock options in 03/2021. JEM -- SAB: Ionis pharmaceuticals, Research Funding: Gilead Sciences. The other authors do not have competing interests, financial or otherwise.
